Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
LLY.USALILY34.BrazilLLY.CanadaLLY.GermanyLLY.SwitzerlandLLY.ArgentinaLLY.MexicoLLYC.AustriaLLYz.UKLLY.France IPO Date
2019-06-26Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.15 | |||||
| Equity-to-Asset | 0.2 | |||||
| Debt-to-Equity | 1.7 | |||||
| Debt-to-EBITDA | 2.06 | |||||
| Interest Coverage | 21.43 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 8.49 | |||||
| Beneish M-Score | -2.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.8 | |||||
| 3-Year EBITDA Growth Rate | 9.1 | |||||
| 3-Year EPS without NRI Growth Rate | 11.6 | |||||
| 3-Year FCF Growth Rate | 11 | |||||
| 3-Year Book Growth Rate | 60.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 29.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.56 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.53 | |||||
| 9-Day RSI | 43.64 | |||||
| 14-Day RSI | 51.25 | |||||
| 6-1 Month Momentum % | 64.12 | |||||
| 12-1 Month Momentum % | 58.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.13 | |||||
| Quick Ratio | 0.87 | |||||
| Cash Ratio | 0.15 | |||||
| Days Inventory | 237.91 | |||||
| Days Sales Outstanding | 86.61 | |||||
| Days Payable | 108.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.79 | |||||
| Dividend Payout Ratio | 0.59 | |||||
| 3-Year Dividend Growth Rate | 15 | |||||
| Forward Dividend Yield % | 0.81 | |||||
| 5-Year Yield-on-Cost % | 1.51 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 0.76 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.77 | |||||
| Operating Margin % | 28.12 | |||||
| Net Margin % | 22.01 | |||||
| ROE % | 63.06 | |||||
| ROA % | 12.89 | |||||
| ROIC % | 20.63 | |||||
| ROC (Joel Greenblatt) % | 76.07 | |||||
| ROCE % | 22.74 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 77.59 | |||||
| Forward PE Ratio | 43.29 | |||||
| PE Ratio without NRI | 77.59 | |||||
| Shiller PE Ratio | 109.3 | |||||
| Price-to-Owner-Earnings | 132.98 | |||||
| PEG Ratio | 3.94 | |||||
| PS Ratio | 16.84 | |||||
| PB Ratio | 47.19 | |||||
| Price-to-Tangible-Book | 5783.33 | |||||
| Price-to-Free-Cash-Flow | 154.8 | |||||
| Price-to-Operating-Cash-Flow | 86.59 | |||||
| EV-to-EBIT | 70.29 | |||||
| EV-to-Forward-EBIT | 40.56 | |||||
| EV-to-EBITDA | 59 | |||||
| EV-to-Forward-EBITDA | 34.67 | |||||
| EV-to-Revenue | 18.26 | |||||
| EV-to-Forward-Revenue | 13.66 | |||||
| EV-to-FCF | 167.56 | |||||
| Price-to-Projected-FCF | 7.24 | |||||
| Price-to-Median-PS-Value | 3.4 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.74 | |||||
| Price-to-Graham-Number | 149.14 | |||||
| Earnings Yield (Greenblatt) % | 1.43 | |||||
| Forward Rate of Return (Yacktman) % | 17.18 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eli Lilly and Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 28,076.623 | ||
| EPS (TTM) (€) | 6.743 | ||
| Beta | -0.03 | ||
| Volatility % | 34.51 | ||
| 14-Day RSI | 51.25 | ||
| 14-Day ATR (€) | 6.742341 | ||
| 20-Day SMA (€) | 532.025 | ||
| 12-1 Month Momentum % | 58.07 | ||
| 52-Week Range (€) | 290.75 - 560.5 | ||
| Shares Outstanding (Mil) | 949.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eli Lilly and Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eli Lilly and Co Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eli Lilly and Co Frequently Asked Questions
What is Eli Lilly and Co(WBO:LLYC)'s stock price today?
The current price of WBO:LLYC is €520.50. The 52 week high of WBO:LLYC is €560.50 and 52 week low is €290.75.
When is next earnings date of Eli Lilly and Co(WBO:LLYC)?
The next earnings date of Eli Lilly and Co(WBO:LLYC) is 2023-10-31.
Does Eli Lilly and Co(WBO:LLYC) pay dividends? If so, how much?
The Dividend Yield %  of Eli Lilly and Co(WBO:LLYC) is 0.79% (As of Today), Highest Dividend Payout Ratio of Eli Lilly and Co(WBO:LLYC) was 0.89. The lowest was 0.44. And the median was 0.57. The  Forward Dividend Yield % of Eli Lilly and Co(WBO:LLYC) is 0.81%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers